1. Home
  2. LPTX vs GLAC Comparison

LPTX vs GLAC Comparison

Compare LPTX & GLAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPTX
  • GLAC
  • Stock Information
  • Founded
  • LPTX 2011
  • GLAC 2021
  • Country
  • LPTX United States
  • GLAC China
  • Employees
  • LPTX N/A
  • GLAC N/A
  • Industry
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • GLAC
  • Sector
  • LPTX Health Care
  • GLAC
  • Exchange
  • LPTX Nasdaq
  • GLAC Nasdaq
  • Market Cap
  • LPTX 117.1M
  • GLAC 95.0M
  • IPO Year
  • LPTX N/A
  • GLAC 2023
  • Fundamental
  • Price
  • LPTX $2.74
  • GLAC $10.59
  • Analyst Decision
  • LPTX Strong Buy
  • GLAC
  • Analyst Count
  • LPTX 4
  • GLAC 0
  • Target Price
  • LPTX $8.63
  • GLAC N/A
  • AVG Volume (30 Days)
  • LPTX 452.0K
  • GLAC 154.6K
  • Earning Date
  • LPTX 11-13-2024
  • GLAC 01-01-0001
  • Dividend Yield
  • LPTX N/A
  • GLAC N/A
  • EPS Growth
  • LPTX N/A
  • GLAC N/A
  • EPS
  • LPTX N/A
  • GLAC N/A
  • Revenue
  • LPTX N/A
  • GLAC N/A
  • Revenue This Year
  • LPTX N/A
  • GLAC N/A
  • Revenue Next Year
  • LPTX N/A
  • GLAC N/A
  • P/E Ratio
  • LPTX N/A
  • GLAC $41.19
  • Revenue Growth
  • LPTX N/A
  • GLAC N/A
  • 52 Week Low
  • LPTX $1.55
  • GLAC $10.04
  • 52 Week High
  • LPTX $5.00
  • GLAC $10.60
  • Technical
  • Relative Strength Index (RSI)
  • LPTX 39.77
  • GLAC N/A
  • Support Level
  • LPTX $3.40
  • GLAC N/A
  • Resistance Level
  • LPTX $3.61
  • GLAC N/A
  • Average True Range (ATR)
  • LPTX 0.40
  • GLAC 0.00
  • MACD
  • LPTX -0.13
  • GLAC 0.00
  • Stochastic Oscillator
  • LPTX 1.91
  • GLAC 0.00

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

About GLAC Global Lights Acquisition Corp

Global Lights Acquisition Corp is a blank check company.

Share on Social Networks: